ProPhase Labs, Inc. · OTC:PRPH
ProPhase Labs — Quigley — Proxy Contest (May 2009)
30 slides from ProPhase Labs's proxy contest presentation, May 5, 2009
Slide 1: The Quigley Corporation: The Nature of Human Health
QUIGLEY CORPORATION The Nature of Human Health May 2009
Slide 2: Agenda
6, 2 Agenda QUIGLEY + Introductions Key Messages Corporate Overview Quigley Pharma Progress and Update OTC Products Management, Board of Directors, Corporate Governance Why dissident slate is not in the best interest of The Quigley Corporation's stockholders
Slide 3: Introduction
Introduction we QUIGLEY GUY J. QUIGLEY Founder, Chairman of the Board, President, and CEO. 20 years with the Company 20 years experience managing a public campany. Extensive expertise in marketing, manufacturing, and business management GERARD M. GLEESON Vice President, CFO and a Director. 11 years
Slide 4: Key Messages
od Key Messages QUIGLEY + The Quigley Corporation has the right plan to create long-term stockholder value + The Quigley Corporation has in place a highly-experienced Board and management team with significant industry expertise to enhance stockholder value for long-term growth + Quigley Pharma has
Slide 5: Corporate Overview
od Corporate Overview QUIGLEY The Quigley Corporation is a natural health medical science company comprised of three business segments: Quigley Pharma Ine. (Ethical Pharmaceutical) - Research and Development into potential ethical pharmaceutical products COLD-EEZE® (Cold Remedy) - Markets leading OT
Slide 6: Company Evolution and Highlights
Me Company Evolution and Highlights QUIGLEY Quigley (Re 2 Suet re a et ‘nfonaton Sy = 4) nay Ara HSH ‘Ses Pouty (R39 Pas uy xed 1-40) Lanes Saris of tutes on rc ite Dee estes ete ees = (R44) Boats tlt spat pons ‘> frtetg he comand aetna Ta itl sensory reve ron ns posib se Poeton Ds erat et y = B06 e
Slide 7: Long Term Strategy to Build Stockholder Value
4 Long Term Strategy to Build Stockholder Value QUIGLEY + Established Quigley Pharma in 2001 to focus an disease states with unmet needs + Focus on Research & Development in naturally-derived compounds distributed through RX, OTC and Veterinary channels + Utilize share of profits from successful OTC
Slide 8: Quigley Pharma Strategic Relationships
Quigley Pharma Strategic Relationships of by QUIGLEY Scientific Advisory Board Affiliation Expertise Dr. Phillip Raskin Texas Southern University Diabetes Complications Dr. Phillip Low Mayo Clinic Author of leading Text in field of Diabetic Peripheral Neuropathy Professor William McBride David Geffe
Slide 9: Quigley Pharma Research Pipeline (2001-2009)
Quigley Pharma Research Pipeline (2001-2009) St QUIGLEY CORPORATION Pre- clinical Compound Vv QR-333 Diabetic Peripheral Neuropathy QR-441(a) aR-448(a) Veterinary Anti-Viral QR-440-443.449 Broad Spectrum Anti-Inflammatory OR-336 Systemic Radiation
Slide 10: QR-333 Diabetic Peripheral Neuropathy (DPN) Timeline
QR-333 % Diabetic Peripheral QUIGLEY Neuropathy (DPN) Timeline GR-333 Diabetic Peripheral Neuropathy Formulation validation and sabi Phase study FDAINO meeting 7 R333 shows significant limprovementin dist sensory ‘nerve function ingicating possible disease Results tromproot of ‘modification concept
Slide 11: QR-333 Diabetic Peripheral Neuropathy
we QR-333 T Diabetic Peripheral Neuropathy QU; GEEY Unexpected Phase Ilb clinical study showed significant increase in nerve conduction speed and strength of sensory nerve signals indicating potential disease modification Study Findings Suggest + Study drug has potential to stop and/or reverse nerve
Slide 12: QR-333 Next Steps To Enhance Stockholder Value
we QR-333 Diabetic Peripheral Neuropathy QUIGLEY Next Steps To Enhance Stockholder Value Multiple avenues can be pursued for these formulations and are being evaluated: + Opportunities include: - Potential partnering and licensure with pharmaceutical companies - Co-development and co-promotional int
Slide 13: Quigley Pharma Has Made Significant Progress With QR-333
we QUIGLEY QUIGLEY PHARMA HAS MADE SIGNIFICANT PROGRESS WITH QR-333 AND HAS OTHER POTENTIAL RX FORMULATIONS IN ITS PIPELINE
Slide 14: Quigley Pharma Additional Pipeline Research Programs
4 Quigley Pharma Additional T Pipeline Research Programs QU: GLEY Program Description & Clinical Status: QR-440-443-449 ~ Broad Spectrum Anti-Inflamatory + Anti-Inflammatory compound (naturally derived broad spectrum) to manage, reduce or normalize pro-inflammatory cytokines, decrease free radicals
Slide 15: Quigley Pharma Summary
od Quigley Pharma QUIGLEY Summary Uniquely positioned in emerging market for naturally sourced therapeutics peveral compounds in development from pre-clinical through Phase II trials Lead compound (QR-333) targets unmet need for estimated 20 million diabetics at risk for DPN Unexpected results of Ph
Slide 16: Franchise Background
we Franchise Background QUIGLEY + Over the past 7 years, an investment in COLD-EEZE® growth has been managed in order to generate $28 million in funding to support the Pharma Division + COLD-EEZE remains a viable brand with consumer and retail trade in all channels and achieved the following ~ Gener
Slide 17: The Quigley Corporation Summary
4 The Quigley Corporation QUIGLEY Summary + Management and the Board recognized an enormous opportunity to leverage its expertise in the nutraceutical arena by utilizing capital generated by COLD-EEZE to fund an ethical pharmaceutical initiative, as part of its business plan to achieve long- term st
Slide 18: Management, Board of Directors, Corporate Governance
od QUIGLEY Management, Board of Directors, Corporate Governance
Slide 19: Focused On Corporate Governance
Focused On Corporate % Governance QUIGLEY Board serves at the pleasure of the stockholders — No staggered or classified Board of Directors; all directors stand for election annually — Stockholders can calla special meeting The Company does not maintain any change of control arrangements or severance
Slide 20: Executive Compensation Discipline
od Executive Compensation Discipline QUIGLEY Our Board is committed to aligning executive compensation with stockholder interests Compensation packages are determined by the Compensation Committee, comprised solely of independent directors In December 2008, as part of the Company's efforts to reduce
Slide 21: Seasoned Board of Directors
Seasoned Board of Directors wt QUIGLEY + Our Board members are highly skilled in public company leadership, marketing, operating, finance, accounting and averall executive management + Our existing directors, nominated for re-election have extensive public company experience and the necessary depth
Slide 22: Seasoned Board of Directors
Seasoned Board of Directors 4 QUIGLEY JACQUELINE F. LEWIS (Independent Director) Quigley board - 12 years President of CPC, a list management and marketing company. Co-founded and managed D.A. Lewis, Inc., a direct mail advertising company far 27 years; founding director Suburban Community Bank and
Slide 23: The Dissident Slate Lacks The Necessary Experience
od The Dissident Slate Lacks QUIGLEY The Necessary Experience + Mr. Karkus’ slate appears to be largely comprised of friends + The dissident slate of nominees adds little or no value or expertise to the Quigley Corporation Board of Directors As a group, the dissident nominees have: - No relevant ind
Slide 24: The Dissident Slate Lacks Experience
The Dissident Slate Lacks Experience of by QUIGLEY TED KARKUS Managing member of Forrester Financial, management consulting Opportunistic private investor. No experience serving ana hoard of a public company. No manufacturing experience Approached a member of The Quigley Corporation Board in 2008 in
Slide 25: The Dissident Group Seeks Control But Has No Plan
¥ The Dissident Group Seeks QUIGLEY Control But Has No Plan + Karkus provides no plan to maximize stockholder value + His “plan of action” is boilerplate, uninspired and uninformed: — Review performance, compensation and composition of management — Look at structure of the company to maximize profit
Slide 26: False and Misleading Statements by Karkus in Connection with Sale of Darius
False and Misleading Statements by Karkus in Connection with Sale of Darius Claim: The Board approved the sale of "key revenue producing assets” Fact. Darius’ revenues were significantly stagnating and decreasing in the three years wt QUIGLEY prior to disposal and the health and wellness segment rep
Slide 27: False and Misleading Statements by Karkus in Connection with Sale of Darius
we False and Misleading Statements Y by Karkus in Connection with QUIGLEY Sale of Darius Claim: The Board approved the sale ..."to a company for which the CEO's brother is a major shareholder” Fact: Prior to the sale of Darius by The Quigley Corporation on February 29, 2008, Gary Quigley was not a s
Slide 28: Misleading Statement by Karkus In Connection With Company's Pace of Drug Development
Misleading Statement by Karkus 4 In Connection With Company’s QUIGLEY Pace of Drug Development Claim: Fact: Additional funding for R&D would have accelerated the slow, 8 year development in the Pharma division Quigley Pharma drug development is faster than big Pharma and at much lower cost (Source P
Slide 29: Vote the White Proxy Card
od QUIGLEY VOTE THE WHITE PROXY CARD
Slide 30: Safe Harbor Statement
wt Safe Harbor Statement QUIGLEY Certain Risk Factors In addition to_historical information, this presentation contains forward-lookin statements. These forward-looking statements are subject to certain risks an uncertainties that could cause actual results to differ materially’ from those reflected